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Abstract
Prevention of early recurrent ischaemic stroke remains a priority in people with TIA or ischaemic stroke. A number of
trials have recently been completed assessing the efficacy of short-term dual antiplatelet therapy (DAPT) versus single
antiplatelet therapy early after minor or moderate stroke or high-risk TIA. We present an Expedited Recommendation
for use of dual antiplatelet therapy early after ischaemic stroke and TIA on behalf of the ESO Guideline Board. We make
a strong recommendation based on high quality of evidence for use of 21-days of dual antiplatelet therapy with aspirin
and clopidogrel in people with a non-cardioembolic minor ischaemic stroke or high-risk TIA in the past 24 hours. We
make a weak recommendation based on moderate quality evidence for 30-days of dual antiplatelet therapy with aspirin
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Introduction
Prevention of early recurrent ischaemic stroke
remains a priority in people with TIA or ischaemic
stroke. A number of trials have recently been com-
pleted assessing the efficacy of short-term dual anti-
platelet therapy (DAPT) versus single antiplatelet
therapy early after minor or moderate stroke and
high-risk TIA.
The role of dual antiplatelet treatment will be con-
sidered in both the European Stroke Organisation’s
guidelines for management of TIA and guidelines for
secondary prevention of ischaemic stroke, yet their
use is rapidly increasing. Therefore, in advance
of their publication, we present an Expedited
Recommendation for use of dual antiplatelet therapy
early after minor ischaemic stroke and TIA on behalf
of the ESO Guideline Board.
We considered evidence for use of DAPT
early after minor or moderate ischaemic stroke and
high-risk TIA. We considered DAPT with clopidogrel
and aspirin separately from DAPT with ticagrelor
and aspirin.
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This Expedited Recommendation was developed by a
sub-group of the TIA Management and Stroke
Secondary Prevention guidelines Module Working
Groups (MWG). The composition of these groups
was approved by the ESO Guidelines Board and the
ESO Executive Committee, based on a review of the
intellectual and financial disclosures of the proposed
members. ESO guidelines follow GRADE methodolo-
gy1 and the ESO Standard Operating Procedures.2 In
brief, PICO (Population, Intervention, Comparator,
Outcome) questions and further outcomes of clinical
interest are identified. The relevance of possible out-
comes is voted on by all members of the MWG using
Delphi methods.
For each PICO question, systematic searches of
PubMed, covering the period from the inception of
each database to 15th September 2020, were conducted
by the ESO Guidelines methodologist, Avtar Lal (AL).
Two authors independently screened the titles and
abstracts of publications identified from the searches
and assessed the full text of potentially relevant studies.
Within one week of ictus was defined as ‘early’. This
recommendation only considered data on adults.
The risk of selection, performance, detection, attri-
tion and reporting biases in each randomised trial was
assessed using the Cochrane Collaboration’s tool, and
heterogeneity across studies was assessed using
Cochran’s Q (reported as a p value) and I2 statistics.
For each PICO question and each outcome, the quality
of evidence was rated using the GRADEpro Guideline
Development Tool (McMaster University, 2015; devel-
oped by Evidence Prime, Inc.) as high, moderate, low
or very low. An evidence-based recommendation
according to the GRADE evidence profiles and the
ESO standard operating procedure was then developed
and reviewed by all MWG members and modified
using a Delphi approach until consensus was reached.
The document was subsequently reviewed and
approved by two external reviewers, and members of
the ESO Guidelines Board and Executive Committee.
We developed 2 PICO questions;
1. In people with a non-cardioembolic minor ischaemic
stroke or high-risk TIA, does early initiation of dual
antiplatelet therapy with aspirin and clopidogrel,
compared to aspirin monotherapy, reduce the risk
of stroke recurrence?
2. In people with a non-cardioembolic mild to moder-
ate ischaemic stroke or high-risk TIA, does early
initiation of dual antiplatelet therapy with aspirin
and ticagrelor, compared to aspirin monotherapy,
reduce the risk of stroke recurrence?
Summary of current evidence
Our literature search identified four RCTs3–6
which tested DAPT early after minor or moderate
ischaemic stroke and TIA. Three RCTs (CHANCE,
FASTER, POINT) tested the combination of
aspirin and clopidogrel versus aspirin and placebo
and have already been summarised in a systematic
review and meta-analysis.7 Only people with minor
ischaemic stroke (NIHSS 3) and high-risk
TIA were included in these trials. Minor ischaemic
stroke was defined as NIHSS of 3 or less in the
POINT and CHANCE trials and high-risk TIA as an
ABCD2 score of 4 or more. In the FASTER trial,
people with TIA needed to have either weakness or
speech disturbance as part of the symptom complex
with a duration of 5minutes or more to qualify for
inclusion in the study.
One RCT (THALES) tested aspirin and ticagrelor
versus aspirin and placebo in people with minor or
moderate stroke and high-risk TIA.6
Patients with lower-risk TIA or only possible TIA or
patients not assessed by a stroke specialist were not
included in any of the identified randomised trials. In
forming this recommendation we included outcomes
up to 90-days after randomisation.
Summary of data for PICO 1
• In people with a non-cardioembolic minor stroke or
high-risk TIA, does early initiation of dual antipla-
telet therapy with aspirin and clopidogrel, compared
to aspirin monotherapy, reduce the risk of recurrent
ischaemic stroke?
The three RCTs included a total of 10,447 patients.
Compared with aspirin alone, dual antiplatelet therapy
with clopidogrel and aspirin;
• significantly reduced the risk of ischaemic stroke at
90 days (RR 0.70, 95% CI 0.61 to 0.81, I2¼ 0%,
absolute reduction 2.6%, high quality evidence,
n¼ 2 trials, 10051 participants).
• significantly reduced the risk of any stroke at
90 days (RR 0.71, 95% CI 0.62 to 0.82, I2¼ 0%,
absolute reduction 2.6%, high quality evidence,
n¼ 3 trials 10244 participants).
• non-significantly increased risk of haemorrhagic
stroke at 90 days (RR 1.18, 95% CI 0.53 to 2.65,
absolute increase 0.1%, I2¼ 0%, low quality evi-
dence, n¼ 2 trials, 10051 participants).
• Non-significantly increased risk of major bleeding at
90 days (RR 1.73, 95% CI 0.69 to 4.30, I2¼ 37%,
absolute increase 0.2% moderate quality evidence,
n¼ 3 trials, 10443 participants).
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Ischaemic stroke was the most common stroke event
and was more common than haemorrhagic stroke
(total of 786 ischaemic strokes, 23 haemorrhagic
strokes).
A pooled analysis of data from the CHANCE and
POINT trials found that the benefit of dual antiplatelet
therapy with clopidogrel and aspirin was confined to
the first 21 days after minor ischaemic stroke and TIA.8
Moreover, during the chronic phase, large RCTs of
aspirin and clopidogrel vs antiplatelet monotherapy
including the CHARISMA,9 SPS210 and MATCH11
trials, have not shown any net benefit; this is because
any reduction in ischaemic events has been largely
offset by bleeding, the risk of which is cumulative
over time.
Summary of data for PICO 2
• In people with a non-cardioembolic mild to moder-
ate ischaemic stroke or high-risk TIA, does early
initiation of dual antiplatelet therapy with aspirin
and ticagrelor, compared to aspirin monotherapy,
reduce the risk of stroke recurrence?
The THALES study was the only identified trial and
included 11,016 people with high-risk TIA or minor
ischaemic stroke. Participants were given either ticagre-
lor plus aspirin or matching placebo plus aspirin.
Outcomes were assessed at 30-days. Compared with
aspirin alone, dual antiplatelet therapy with ticagrelor
and aspirin;
• significantly reduced the risk of ischaemic stroke at
30-days (RR 0.79, 95% CI 0.68 to 0.93, absolute
reduction 1.3%, moderate quality evidence).
• significantly reduced the risk of any stroke at 30-
days (RR 0.81, 95% CI 0.69 to 0.95, absolute reduc-
tion 1.2%, moderate quality evidence).
• significantly increased risk of intracranial haemor-
rhage (HR 3.33, 95% CI 1.34 to 8.28, absolute risk
increase 0.3%, low quality evidence).
• significantly increased the risk of severe bleeding
(HR 3.99, 95% CI 1.74 to 9.14, P ¼ 0.001, absolute
risk increase of 0.4%, low quality evidence).
Additional information
Across 3 trials, treatment with an aspirin and clopidog-
rel based DAPT regimen for 21 days after a high-risk
TIA or minor stroke would be expected to prevent 26
ischaemic strokes for every 1000 patients treated but
may not increase risk of intracranial haemorrhage.
In the one included study, treatment with an aspirin-
ticagrelor based DAPT regimen for 30 days after high-
risk TIA or minor or moderate stroke would be
expected to prevent 13 ischaemic strokes for every
1000 patients treated but may be associated with 2
extra cases of haemorrhagic stroke.
Considerations before starting DAPT
Brain imaging should always be performed prior to
initiation of dual antiplatelet therapy.
Dual antiplatelet therapy should be started as soon
as possible, within the first twenty-four hours after
symptom onset.
The definition of minor ischaemic stroke (NIHSS of
3 or less) was consistent in the trials of clopidogrel plus
aspirin whilst high-risk TIA was defined as an ABCD2
score of 4 or more, or by other high-risk features. In the
only study of ticagrelor plus aspirin, people with mod-
erate and minor ischaemic stroke were included
(NIHSS of 5 or less) and high risk TIA was defined
as either an ABCD2 score of 6 or more (provided
motor or speech symptoms were present), or by being
accompanied by evidence of symptomatic carotid or
intracranial atherosclerotic disease. However, less
than 10% of patients were included in the trial due to
a TIA. This should be considered when deciding on a
Recommendation 1
In people with a non-cardioembolic minor ischaemic stroke
(NIHSS score of 3 or less) or high-risk TIA (ABCD2 score of 4
or more) in the past 24 hours, we recommend 21-days of dual
antiplatelet therapy with aspirin and clopidogrel, followed by
antiplatelet monotherapy thereafter.
Quality of evidence: High 
Strength of recommendation: Strong for intervention ""
Recommendation 2
In people with non-cardioembolic mild to moderate ischaemic
stroke (NIHSS of 5 or less) or high-risk TIA (ABCD2 score of
6 or more or other high-risk features*) in the past 24 hours,
we suggest 30-days of dual antiplatelet therapy with aspirin and
ticagrelor followed by antiplatelet monotherapy thereafter.
*defined as either intracranial atherosclerotic disease or at least
50% stenosis in an internal carotid artery that could account
for the presentation.
Quality of evidence: Moderate 
Strength of recommendation: Weak for intervention "?
Expert consensus statement
In people with acute non-cardioembolic low risk TIA or in whom
the diagnosis is uncertain, 11/11 experts voted against use of
dual antiplatelet therapy over monotherapy
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dual antiplatelet therapy regimen after minor stroke
and TIA.
People with high grade carotid stenosis and planned
revascularisation were excluded from POINT,
CHANCE and THALES. In addition, people with a
clear indication for anticoagulation (such as fibrilla-
tion, mechanical heart valve) or recognised increased
risk of bleeding were excluded. DAPT should not rou-
tinely be used in people with an indication for
anticoagulation.
Loading and maintenance doses
The single loading dose of clopidogrel used in the trials
varied from 300mg to 600mg. We suggest giving a
single loading dose of 300mg of clopidogrel in patients
not already taking the relevant medication, followed by
the daily maintenance dose for up to 21 days. The dose
of aspirin used in the trials varied from 50mg to 325mg
and was at the treating physician’s discretion for up to
21 days.
In the THALES study, a 180mg loading dose of
ticagrelor and a single loading dose of 300 or 325mg
of aspirin was used. This was followed by 90mg twice
daily of ticagrelor and 75 to 100mg of aspirin. We
suggest following this dosing regimen.
Choice of drug regimen
Some people with minor stroke and TIA would have
been eligible for the included trials of clopidogrel based
DAPT and the trial of ticagrelor based DAPT. Because
there are three trials of clopidogrel based DAPT with
relevant outcomes and there was no significant increase
in intracranial haemorrhage, the level of certainty
regarding the available evidence and the strength of
the recommendation was rated higher for clopidogrel
based DAPT than for ticagrelor based DAPT.
However, it should be noted that the sample size of
the THALES trial was similar to the combined
sample size of the three clopidogrel based trials. In
addition, the THALES trial allowed inclusion of
people with more severe stroke so the bleeding rate
cannot be directly compared across the clopidogrel
and ticagrelor trials. DAPT with ticagrelor and aspirin
should be considered as an alternative to
clopidogrel based DAPT, particularly in people
known to be intolerant of clopidogrel or in people
who have moderate stroke (NIHSS 4 or 5) and no
other contraindication.
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